TG Therapeutics, Inc. (NASDAQ:TGTX) Position Boosted by HighTower Advisors LLC

HighTower Advisors LLC lifted its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 19.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,526 shares of the biopharmaceutical company’s stock after buying an additional 2,053 shares during the quarter. HighTower Advisors LLC’s holdings in TG Therapeutics were worth $294,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. PFM Health Sciences LP acquired a new position in TG Therapeutics during the 3rd quarter valued at $5,459,000. PDT Partners LLC acquired a new position in TG Therapeutics during the 3rd quarter valued at about $1,419,000. Captrust Financial Advisors raised its position in shares of TG Therapeutics by 21.1% during the 3rd quarter. Captrust Financial Advisors now owns 30,327 shares of the biopharmaceutical company’s stock valued at $709,000 after acquiring an additional 5,279 shares during the last quarter. Public Sector Pension Investment Board bought a new stake in shares of TG Therapeutics in the 3rd quarter valued at about $6,619,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in TG Therapeutics by 12.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,147 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 3,347 shares during the period. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $32.26 on Tuesday. The firm has a market capitalization of $5.02 billion, a price-to-earnings ratio of -322.57 and a beta of 2.25. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The business’s 50-day moving average price is $29.62 and its 200-day moving average price is $24.01. TG Therapeutics, Inc. has a 12 month low of $12.84 and a 12 month high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. During the same quarter in the prior year, the business earned $0.73 earnings per share. The firm’s quarterly revenue was down 49.4% on a year-over-year basis. Equities research analysts forecast that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

Insider Buying and Selling

In other news, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the transaction, the director now directly owns 100,195 shares in the company, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

TGTX has been the topic of several recent research reports. JPMorgan Chase & Co. lifted their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. StockNews.com downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday. The Goldman Sachs Group boosted their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. TD Cowen began coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target for the company. Finally, HC Wainwright boosted their target price on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.